Upcoming Trials

A diagnosis of cancer is life-changing.

Every day our researchers and clinicians are working to achieve our shared goal of one treatment for all cancers.

TROG Cancer Research clinical trials are focused on improving treatments and outcomes for people with cancer. We have been conducting clinical trials for 30 years that rigorously test new methods for treating cancer. We value all contributions whether by participation in a clinical trial or a financial contribution to keep our clinical trials progressing.

Idea’s for new cancer research trials are proposed by our members, who are oncologists and other health professionals that see a need to improve the treatments and outcomes for their patients. A trial proposal is accepted for development after it has been rigorously reviewed by experts in the field, supported by the TROG Cancer Research Membership and approved by the TROG Cancer Research Scientific Committee. 

We have several upcoming proposed trials that will be seeking eligible participants. Please follow the links below to learn more.

research trials, Upcoming Trials, TROG Cancer Research

TROG 18.03

Atezolizumab in low risk HPV OPSCC

AGITG TROG 21D RESOLUTE

Randomised Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

ANZGOG TROG 21.04 ADELE

ADjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk EndometriaL cancer (ADELE): a randomised phase 2 trial

ANZUP 1801 TROG 21.02 DASL-HiCaP

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

TROG 20.03 – AVATAR

A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer

SEAFARER

RTQA: Sensitivity assessment system to improve quality in Radiation Oncology treatment

TROG 18.07

Particle Therapy Registry

VESPA

RTQA: Virtual EPID Standard Phantom Audit

Note: You are welcome to contact us to give comments on the content of this website, but please note however that we are unable to answer individual patient enquiry relating to your cancer or treatments. Any clinical questions should be referred to your GP, oncologist or specialist.